AI assistant
Insight Molecular Diagnostics Inc. — Director's Dealing 2022
Dec 9, 2022
34238_dirs_2022-12-09_92d6815e-9533-4964-ba82-0eadc6487ab4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Oncocyte Corp (OCX)
CIK: 0001642380
Period of Report: 2022-12-02
Reporting Person: Riggs Josh (Interim CEO)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock, no par value | 2308 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Option to Purchase Common Stock | $1.33 | 2030-07-22 | Common Stock (125000) | Direct | |
| Option to Purchase Common Stock | $5.34 | 2031-02-25 | Common Stock (50012) | Direct | |
| Option to Purchase Common Stock | $1.39 | 2032-03-24 | Common Stock (30000) | Direct | |
| Option to Purchase Common Stock | $1.17 | 2032-05-03 | Common Stock (10000) | Direct | |
| Option to Purchase Common Stock | $0.4644 | 2032-12-07 | Common Stock (250000) | Direct |
Footnotes
F1: The Restricted Stock Units vested on May 22, 2021.
F2: 25% of the options will become exercisable after one year of Reporting Person's continuous employment with Issuer from the effective date of grant, and the balance will become exercisable in 36 equal monthly installments commencing one year after the date of grant subject to Reporting Person's continued employment with Issuer on the applicable vesting dates.
F3: 100% of the options will become exercisable after one year of Reporting Person's continuous employment with Issuer from the effective date of grant.